INCY Incyte Corporation - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 5, 2026 10-K/10-Q Jul 28, 2026
$114.98
· of 52w range
· above low
· to high
$82.8252w low
$132.6052w high
Market Cap (MRQ)
$23.11B
P/E (TTM)
14.6
EPS (TTM)
$7.85
Revenue (TTM)
$5.82B
your badges
52W Range
$83–$133
Analyst Rating
HOLD
Price Target
$128
P/E
14.6
ROE
30.7%
Net Profit Margin
27.7%
Your badge strip is empty — pin a metric anywhere on this page.
INCY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$114.97
Market Cap (MRQ)
$23.11B
P/E (TTM)
14.6
EPS (TTM)
$7.85
Revenue (TTM)
$5.82B
ROE (TTM)
30.7%
52W Range
$83–$133
INCY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Sept. 1, 2000 | 2-for-1 | Forward |
| Nov. 10, 1997 | 2-for-1 | Forward |
About Incyte Corporation - Common Stock Company overview from Wikipedia
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993. Subsequently, scientists and chemists were recruited from DuPont to work for Incyte. Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014. Hervé Hoppenot became CEO in January 2014.
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021. The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022. Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024.
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income. Incyte is publicly traded on the NASDAQ under the symbol INCY. Incyte now operates out of North America, Asia, and Europe. Bill Meury became CEO in 2025. Meury replaced Hoppenot, who retired after 11 years in the position.
Pharmaceuticals
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).
In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).
Acquisition history
Incyte has made a total of 3 acquisitions.
Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million.
Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions.
Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees2,844
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$5.14B2016-12-31 → 2025-12-31
EPS$6.412016-12-31 → 2025-12-31
Free Cash Flow·2017-12-31 → 2022-12-31
Net margin27.7%2018-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | INCY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 14.65Y avg ≈113.9 | ≈113.9 | 22.0 | Undervalued | |
| P/S (TTM) | 4.05Y avg ≈4.4 | ≈4.4 | 7.3 | Undervalued | |
| P/B (MRQ) | 3.65Y avg ≈4.0 | ≈4.0 | 6.1 | Undervalued | |
| Price / Cash Flow | 16.15Y avg ≈23.5 | ≈23.5 | 13.9 | Fair value | |
| Price / Tangible Book | 4.55Y avg ≈3.9 | ≈3.9 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | INCY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 30.6%5Y avg ≈16.9% | ≈16.9% | 16.9% | Top tier | |
| EBITDA Margin (TTM) | 32.2%5Y avg ≈18.9% | ≈18.9% | 15.8% | Top tier | |
| Pretax Margin (TTM) | 33.8%5Y avg ≈18.6% | ≈18.6% | 9.3% | Top tier | |
| Net Profit Margin (TTM) | 27.7%5Y avg ≈16.9% | ≈16.9% | 12.7% | Top tier | |
| ROA (TTM) | 23.5%5Y avg ≈12.5% | ≈12.5% | 6.8% | Top tier | |
| ROE (TTM) | 30.7%5Y avg ≈16.0% | ≈16.0% | 18.7% | Top tier | |
| ROIC | 22.7%5Y avg ≈14.3% | ≈14.3% | 16.4% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | INCY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 4.65Y avg ≈3.1 | ≈3.1 | 3.1 | Strong liquidity | |
| Quick Ratio | 2.05Y avg ≈2.0 | ≈2.0 | 1.7 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | INCY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 21.2%5Y avg ≈14.1% | ≈14.1% | · | · | |
| Revenue CAGR 3Y | 14.8%5Y avg ≈12.9% | ≈12.9% | · | · | |
| Revenue CAGR 5Y | 14.0% | · | · | · | |
| EPS YoY | 4173.3%5Y avg ≈1022.2% | ≈1022.2% | · | · | |
| Net Income YoY | 3845.0%5Y avg ≈940.4% | ≈940.4% | · | · | |
| EPS CAGR 3Y | 61.6% | · | · | · | |
| Net Income CAGR 3Y | 55.7% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | INCY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.85Y avg ≈0.7 | ≈0.7 | 0.7 | Top tier | |
| Inventory Turnover | 4.75Y avg ≈5.6 | ≈5.6 | 1.9 | Top tier | |
| Revenue / Employee | ≈$1.8M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
19.2%
Next Report
Oct 26, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 27, 2026 | $3.09 | $2.14 | 44.1% |
| March 31, 2026 | $1.81 | $1.40 | 29.4% | |
| Dec. 31, 2025 | $1.80 | $1.97 | -8.5% | |
| Sept. 30, 2025 | $2.26 | $1.69 | 33.7% | |
| June 30, 2025 | $1.57 | $1.50 | 4.7% | |
| March 31, 2025 | $1.16 | $1.04 | 11.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Cost of Revenue | $372M | $312M | $255M | $207M | $151M | $131M | $114M | $94M | $79M | $58M | $27M | $3M | |
| R&D Expense | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.20B | $1.33B | $582M | $480M | $348M | |
| SG&A Expense | $1.38B | $1.24B | $1.16B | $1.00B | $740M | $517M | $469M | $434M | $366M | $303M | $197M | $166M | |
| Operating Expenses | $3.63B | $4.18B | $3.08B | $2.82B | $2.40B | $2.93B | $1.76B | $1.75B | $1.78B | $961M | $703M | $516M | |
| Operating Income | $1.51B | $61M | $621M | $579M | $586M | $-264M | $402M | $129M | $-243M | $145M | $51M | $-5M | |
| Interest Expense | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $7M | $39M | $46M | $47M | |
| Interest Income | $106M | $129M | $158M | $40M | · | · | · | · | · | · | · | · | |
| Other Non-op | $25M | $13M | $14M | $-519.0K | $11M | $23M | $52M | $32M | $17M | · | · | · | |
| Pretax Income | $1.66B | $317M | $834M | $529M | $570M | $-232M | $487M | $115M | $-312M | $107M | $8M | $-49M | |
| Income Tax | $378M | $284M | $237M | $188M | $-378M | $63M | $40M | $6M | $852.0K | $3M | $1M | $-66.0K | |
| Net Income | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| EPS (Basic) | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | $-1.36 | $2.08 | $0.52 | $-1.53 | $0.55 | $0.04 | $-0.29 | |
| EPS (Diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 | |
| Shares (Basic) | 195,204,000 | 207,110,000 | 223,628,000 | 222,004,000 | 220,428,000 | 218,073,000 | 214,913,000 | 212,383,000 | 204,580,000 | 187,873,000 | 179,601,000 | 167,947,000 | |
| Shares (Diluted) | 200,700,000 | 210,530,000 | 225,928,000 | 223,958,000 | 222,074,000 | 218,073,000 | 217,657,000 | 215,635,000 | 204,580,000 | 194,125,000 | 187,302,000 | 167,947,000 | |
| EBITDA | $1.61B | $151M | · | $647M | $644M | $-212M | $457M | $184M | $-192M | · | · | $37M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10B | $1.69B | $3.21B | $2.95B | $2.06B | $1.51B | $1.83B | $1.16B | $900M | $652M | $521M | $452M | |
| Short-term Investments | · | · | · | · | · | · | $285M | $274M | $270M | $156M | $186M | $148M | |
| Inventory | $101M | $59M | $63M | $42M | $28M | $16M | $11M | $7M | $6M | $4M | $2M | $358.0K | |
| Prepaid Expense | $318M | $169M | $183M | $167M | $126M | $60M | $44M | $79M | $62M | $33M | $18M | $21M | |
| Current Assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B | $2.36B | $2.48B | $1.83B | $1.50B | $994M | $842M | $680M | |
| PP&E (Net) | $731M | $763M | $752M | $739M | $724M | $560M | $378M | $320M | $260M | $168M | $86M | $82M | |
| PP&E (Gross) | $1.11B | $1.09B | $1.02B | $952M | $900M | $704M | $499M | $423M | $334M | $219M | $131M | $116M | |
| Accum. Depreciation | $375M | $328M | $270M | $213M | $176M | $144M | $122M | $103M | $75M | $52M | $45M | $35M | |
| Goodwill | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | · | |
| Intangibles | · | · | · | · | · | · | · | · | $237M | $270M | $12M | $2M | |
| Other Non-current Assets | $18M | $11M | $52M | $25M | $37M | $39M | $49M | $19M | $2M | $3M | $12M | · | |
| Total Assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Accounts Payable | $210M | $197M | $110M | $278M | $172M | $99M | $84M | $104M | $68M | $76M | $30M | $24M | |
| Accrued Liabilities | $1.03B | $1.21B | $936M | $701M | $534M | $378M | $286M | $229M | $199M | $127M | $87M | $62M | |
| Current Liabilities | $1.52B | $1.64B | $1.24B | $1.16B | $854M | $631M | $513M | $425M | $375M | $274M | $168M | $221M | |
| Capital Leases | $15M | $17M | $14M | $14M | $16M | $14M | $12M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $20M | |
| Other Non-current Liabilities | $165M | $168M | $149M | $99M | $70M | $58M | $40M | $22M | $20M | $13M | $48M | $55M | |
| Total Liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B | $950M | $828M | $720M | $672M | $1.22B | $836M | $878M | |
| Long-term Debt | · | · | · | · | · | · | · | $19.09B | $27M | $750M | $750M | $841M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $689M | |
| Common Stock | $198.0K | $193.0K | $224.0K | $223.0K | $221.0K | $219.0K | $216.0K | $213.0K | $211.0K | $189.0K | $187.0K | $171.0K | |
| Retained Earnings | $214M | $-1.07B | $160M | $-437M | $-778M | $-1.73B | $-1.43B | $-1.88B | $-1.99B | $-1.67B | $-1.78B | $-1.79B | |
| AOCI | $25M | $-13M | $13M | $15M | $-19M | $-15M | $-16M | $-10M | $-7M | $-3M | $-809.0K | $2M | |
| Stockholders' Equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B | $2.61B | $2.60B | $1.93B | $1.63B | $419M | $171M | $-82M | |
| Liabilities + Equity | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Shares Outstanding | 198,460,009 | 193,434,305 | 224,286,862 | 222,746,719 | 221,084,433 | 219,489,329 | 216,177,830 | 213,274,660 | 211,262,906 | 188,848,752 | 186,650,249 | 170,876,619 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $93M | $89M | $83M | $68M | $58M | $52M | $55M | $55M | $52M | $58M | $45M | $41M | |
| Stock-based Comp | $249M | $266M | $216M | $188M | $183M | $178M | $167M | $148M | $133M | $96M | $70M | $62M | |
| Deferred Tax | $248M | $-86M | $-159M | $57M | $-466M | $-350.0K | $-377.0K | $-459.0K | $-805.0K | · | · | · | |
| Amort. of Intangibles | $27M | $24M | $22M | $22M | $22M | $22M | $22M | $22M | $22M | $13M | · | · | |
| Other Non-cash | $-463M | $33M | · | $316M | $26M | $-58M | $43M | $24M | · | · | · | · | |
| Operating Cash Flow | $1.41B | $335M | $496M | $970M | $749M | $-125M | $711M | $336M | $-93M | $305M | $89M | $26M | |
| CapEx | · | · | · | $78M | $181M | $187M | $78M | $73M | $111M | $120M | $26M | $28M | |
| Investing Cash Flow | $-103M | $158M | $-208M | $-79M | $-208M | $-269M | $-87M | $-86M | $-350M | $-232M | $-105M | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $649M | · | · | · | |
| Stock Repurchased | $0 | $2.00B | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-2.00B | · | · | · | · | · | · | $649M | · | · | · | |
| Financing Cash Flow | $101M | $-2.02B | $-20M | $-794.0K | $6M | $72M | $46M | $15M | $690M | $45M | $85M | · | |
| Net Change in Cash | $1.41B | $-1.53B | $262M | $894M | $544M | $-319M | $669M | $265M | $247M | $117M | $69M | $-19M | |
| Taxes Paid | $212M | $373M | $378M | $136M | $68M | $71M | $34M | $5M | $6M | $927.0K | · | · | |
| Free Cash Flow | · | · | · | $892M | $568M | $-312M | $633M | $263M | $-204M | · | · | $-2M | |
| Levered FCF | · | · | · | $890M | $565M | $-315M | $631M | $261M | $-211M | · | · | $-48M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 29.5% | 1.5% | · | 17.1% | 19.6% | -9.9% | 18.6% | 6.9% | -15.9% | · | · | -0.94% | |
| Net Margin | 25.0% | 0.77% | · | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | · | · | · | · | |
| Pretax Margin | 32.4% | 7.5% | · | 15.6% | 19.1% | -8.7% | 22.6% | 6.1% | -20.3% | · | · | -9.5% | |
| EBITDA Margin | 31.3% | 3.5% | · | 19.1% | 21.6% | -7.9% | 21.1% | 9.8% | -12.5% | · | · | 7.2% | |
| ROA | 20.8% | 0.53% | · | 6.3% | 22.3% | -8.5% | 14.7% | 4.4% | · | · | · | · | |
| ROE | 27.6% | 0.99% | · | 7.9% | 27.4% | -11.8% | 17.8% | 5.9% | · | · | · | · | |
| ROIC | 22.7% | 0.18% | · | 8.5% | 25.8% | -12.9% | 14.2% | 6.4% | -15.0% | · | · | -0.79% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 2.0 | · | 3.5 | 3.7 | 3.7 | 4.8 | 4.3 | 4.0 | · | · | 3.2 | |
| Quick Ratio | 2.0 | 1.0 | · | 2.6 | 2.4 | 2.4 | 4.1 | 3.4 | 3.1 | · | · | 2.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | -8.4 | |
| Interest Coverage | · | · | · | 217.3 | 307.0 | -121.3 | 216.7 | 83.7 | -35.3 | · | · | -0.1 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | · | 0.6 | 0.7 | 0.8 | 0.7 | 0.8 | 0.8 | · | · | 0.7 | |
| Inventory Turnover | 4.7 | 5.1 | · | 5.9 | 6.8 | 9.4 | 12.4 | 14.0 | 15.0 | · | · | 7.9 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $26.04 | $17.82 | · | $19.62 | $17.05 | $11.90 | $12.02 | $9.03 | $7.72 | · | · | · | |
| Revenue / Share | $25.62 | $20.15 | · | $15.16 | $13.45 | $12.23 | $9.92 | $8.73 | $7.51 | · | · | · | |
| Cash Flow / Share | $7.04 | $1.59 | · | $4.33 | $3.37 | $-0.57 | $3.27 | $1.56 | $-0.45 | · | · | · | |
| Cash / Share | $15.61 | $8.73 | · | $13.25 | $9.31 | $6.89 | $8.48 | $5.46 | $4.26 | · | · | · | |
| EPS (TTM) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.2% | 14.8% | 8.9% | 13.7% | 12.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 12.4% | 11.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 14.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4173.3% | -94.3% | 74.3% | -64.4% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 61.6% | -67.2% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 3845.0% | -94.5% | 75.4% | -64.1% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 55.7% | -67.5% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Net Income TTM | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| Market Cap | $19.60B | $13.36B | · | $17.89B | $16.23B | $19.09B | $18.88B | $13.56B | $20.01B | · | · | · | |
| P/E | 15.4 | 460.5 | 23.7 | 52.8 | 17.2 | -64.0 | 42.6 | 124.7 | -61.9 | 185.7 | 3615.0 | -252.1 | |
| P/S | 3.8 | 3.2 | · | 5.3 | 5.4 | 7.2 | 8.7 | 7.2 | 13.0 | · | · | · | |
| P/B | 3.8 | 3.9 | · | 4.1 | 4.3 | 7.3 | 7.3 | 7.0 | 12.3 | · | · | · | |
| P / Tangible Book | 3.9 | 4.1 | 2.8 | 4.2 | 4.5 | 7.8 | · | · | · | · | · | · | |
| P / Cash Flow | 13.9 | 39.8 | · | 18.4 | 21.7 | -153.2 | 26.6 | 40.3 | -215.2 | · | · | · | |
| P / FCF | · | · | · | 20.1 | 28.5 | -61.2 | 29.8 | 51.6 | -98.1 | · | · | · | |
| Earnings Yield | 6.5% | 0.22% | 4.2% | 1.9% | 5.8% | -1.6% | 2.4% | 0.80% | -1.6% | 0.54% | 0.03% | -0.40% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B | $1.14B | $1.04B | $881M | $1.01B | $919M | $955M | $809M | $927M | $823M | |
| Cost of Revenue | $105M | $105M | $121M | $99M | $79M | $73M | $88M | $86M | $77M | $61M | $70M | $60M | $68M | $57M | $59M | $55M | |
| R&D Expense | $517M | $516M | $611M | $507M | $495M | $437M | $466M | $573M | $1.14B | $429M | $444M | $376M | $401M | $407M | $501M | $384M | |
| SG&A Expense | $352M | $328M | $390M | $329M | $331M | $326M | $327M | $309M | $306M | $300M | $288M | $268M | $284M | $316M | $273M | $266M | |
| Operating Expenses | $976M | $972M | $1.17B | $922M | $685M | $848M | $877M | $992M | $1.52B | $789M | $826M | $704M | $761M | $784M | $857M | $685M | |
| Operating Income | $698M | $301M | $336M | $444M | $530M | $205M | $302M | $146M | $-478M | $92M | $187M | $215M | $194M | $25M | $70M | $138M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $430.0K | · | $623.0K | $655.0K | $469.0K | · | $641.0K | |
| Interest Income | $38M | $34M | $31M | $27M | $25M | $23M | $21M | $19M | $41M | $47M | · | · | · | · | · | · | |
| Other Non-op | $6M | $3M | $6M | $4M | $7M | $8M | $2M | $5M | $8M | $-2M | $-108M | $46M | $43M | $33M | $-14M | $12M | |
| Pretax Income | $752M | $344M | $390M | $482M | $558M | $234M | $314M | $157M | $-390M | $236M | $271M | $234M | $278M | $52M | $81M | $149M | |
| Income Tax | $166M | $40M | $91M | $58M | $153M | $76M | $113M | $50M | $55M | $67M | $70M | $63M | $74M | $30M | $52M | $36M | |
| Net Income | $586M | $303M | $299M | $424M | $405M | $158M | $201M | $106M | $-445M | $170M | $201M | $171M | $204M | $22M | $28M | $113M | |
| EPS (Basic) | $2.92 | $1.52 | $1.51 | $2.17 | $2.09 | $0.82 | $0.89 | $0.55 | $-2.04 | $0.76 | $0.90 | $0.76 | $0.91 | $0.10 | $0.12 | $0.51 | |
| EPS (Diluted) | $2.81 | $1.47 | $1.46 | $2.11 | $2.04 | $0.80 | $0.90 | $0.54 | $-2.04 | $0.75 | $0.89 | $0.76 | $0.90 | $0.10 | $0.13 | $0.50 | |
| Shares (Basic) | 200,378,000 | 199,343,000 | · | 195,670,000 | 193,995,000 | 193,712,000 | · | 192,629,000 | 218,175,000 | 224,484,000 | · | 224,078,000 | 223,248,000 | 222,960,000 | · | 222,415,000 | |
| Shares (Diluted) | 208,216,000 | 206,830,000 | · | 201,429,000 | 198,744,000 | 198,197,000 | · | 195,838,000 | 218,175,000 | 227,219,000 | · | 226,167,000 | 225,649,000 | 225,589,000 | · | 224,175,000 | |
| EBITDA | $698M | $325M | · | $444M | $530M | $228M | · | $146M | $-478M | $114M | · | $215M | $194M | $44M | · | $138M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B | $1.69B | $1.30B | $987M | $3.35B | · | $3.23B | $3.13B | $2.82B | · | $2.69B | |
| Inventory | $113M | $116M | $101M | $83M | $83M | $64M | $59M | $70M | $101M | $64M | · | $57M | $36M | $41M | · | $46M | |
| Prepaid Expense | $253M | $301M | $318M | $369M | $296M | $212M | $169M | $205M | $208M | $189M | · | $172M | $167M | $194M | · | $180M | |
| Current Assets | $6.03B | $5.48B | $5.02B | $4.28B | $3.64B | $3.51B | $3.24B | $2.81B | $2.57B | $4.85B | · | $4.40B | $4.26B | $3.97B | · | $3.82B | |
| PP&E (Net) | $709M | $720M | $731M | $799M | $799M | $765M | $763M | $773M | $762M | $720M | · | $733M | $749M | $742M | · | $716M | |
| PP&E (Gross) | $1.11B | $1.11B | $1.11B | $1.16B | $1.14B | $1.11B | $1.09B | $1.09B | $1.06B | $1.00B | · | $986M | $988M | $967M | · | $918M | |
| Accum. Depreciation | $404M | $389M | $375M | $361M | $346M | $344M | $328M | $316M | $298M | $283M | · | $253M | $239M | $226M | · | $202M | |
| Goodwill | $133M | $133M | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | $156M | $156M | $156M | · | $156M | |
| Other Non-current Assets | $87M | $24M | $18M | $32M | $33M | $30M | $11M | $40M | $22M | $47M | · | $81M | $32M | $21M | · | $24M | |
| Total Assets | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Accounts Payable | $250M | $229M | $210M | $172M | $241M | $196M | $197M | $179M | $148M | $164M | · | $139M | $156M | $56M | · | $163M | |
| Accrued Liabilities | $870M | $1.09B | $1.03B | $948M | $857M | $1.38B | $1.21B | $1.13B | $1.03B | $1.10B | · | $821M | $811M | $825M | · | $700M | |
| Current Liabilities | $1.31B | $1.49B | $1.52B | $1.34B | $1.28B | $1.72B | $1.64B | $1.50B | $1.34B | $1.40B | · | $1.12B | $1.12B | $1.01B | · | $1.01B | |
| Capital Leases | · | · | $15M | · | · | · | $17M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $125M | $127M | $165M | $171M | $180M | $176M | $168M | $145M | $142M | $151M | · | $133M | $140M | $118M | · | $75M | |
| Total Liabilities | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B | $2.00B | $1.84B | $1.66B | $1.74B | · | $1.46B | $1.47B | $1.34B | · | $1.28B | |
| Common Stock | $201.0K | $200.0K | $198.0K | $196.0K | $194.0K | $193.0K | $193.0K | $192.0K | $191.0K | $224.0K | · | $224.0K | $223.0K | $223.0K | · | $222.0K | |
| Retained Earnings | $1.10B | $517M | $214M | $-86M | $-510M | $-915M | $-1.07B | $-1.27B | $-1.38B | $330M | · | $-41M | $-212M | $-416M | · | $-466M | |
| AOCI | $20M | $22M | $25M | $15M | $13M | $-6M | $-13M | $16M | $-5M | $-6M | · | $23M | $27M | $21M | · | $-29M | |
| Stockholders' Equity | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B | $3.17B | $3.00B | $5.39B | $5.19B | $4.93B | $4.74B | $4.46B | $4.37B | $4.23B | |
| Liabilities + Equity | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Shares Outstanding | 200,977,687 | 199,948,401 | 198,460,009 | 196,130,993 | 194,123,265 | 193,783,446 | 193,434,305 | 192,798,328 | 191,572,449 | 224,533,449 | · | 224,101,839 | 223,338,330 | 223,061,787 | · | 222,454,839 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $26M | $24M | $24M | $24M | $23M | $22M | $23M | $23M | $22M | $22M | $22M | $21M | $20M | $19M | $18M | $17M | |
| Stock-based Comp | $67M | $64M | $62M | $62M | $65M | $61M | $72M | $78M | $57M | $60M | $60M | $48M | $55M | $53M | $53M | $45M | |
| Other Non-cash | · | $-22M | · | · | · | $25M | · | · | · | $-32M | · | · | · | $-200M | · | · | |
| Operating Cash Flow | $508M | $369M | $543M | $559M | $45M | $266M | $381M | $311M | $-576M | $219M | $148M | $148M | $307M | $-106M | $284M | $296M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $28M | |
| Investing Cash Flow | $-52M | $-88M | $-37M | $-47M | $-19M | $1M | $-21M | $38M | $214M | $-73M | $-154M | $-17M | $-7M | $-29M | $-21M | $-28M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $103.0K | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $65M | $85M | $138M | $-13M | $-11M | $-13M | $20M | $-32M | $-2.00B | $-12M | $346.0K | $-37M | $13M | $4M | $-2M | $-14M | |
| Net Change in Cash | $521M | $363M | $643M | $500M | $13M | $254M | $384M | $317M | $-2.36B | $133M | $-14M | $96M | $310M | $-130M | $261M | $255M | |
| Taxes Paid | $15M | $-9M | $27M | $7M | $177M | $844.0K | $70M | $73M | $227M | $3M | $125M | $116M | $130M | $7M | $20M | $40M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.7% | 23.7% | · | 32.5% | 43.6% | 19.5% | · | 12.8% | -45.8% | 10.4% | · | 23.4% | 20.3% | 3.1% | · | 16.8% | |
| Net Margin | 35.0% | 23.8% | · | 31.1% | 33.3% | 15.0% | · | 9.4% | -42.6% | 19.2% | · | 18.6% | 21.3% | 2.7% | · | 13.7% | |
| Pretax Margin | 44.9% | 27.0% | · | 35.3% | 45.9% | 22.2% | · | 13.8% | -37.3% | 26.8% | · | 25.4% | 29.1% | 6.4% | · | 18.1% | |
| EBITDA Margin | 41.7% | 25.5% | · | 32.5% | 43.6% | 21.6% | · | 12.8% | -45.8% | 12.9% | · | 23.4% | 20.3% | 5.4% | · | 16.8% | |
| ROA | 8.6% | 4.6% | · | 7.5% | 7.7% | 2.5% | · | 1.9% | -8.2% | 2.6% | · | 2.9% | 3.5% | 0.40% | · | 2.3% | |
| ROE | 11.1% | 6.5% | · | 10.8% | 11.3% | 3.5% | · | 2.6% | -11.5% | 3.4% | · | 3.7% | 4.6% | 0.52% | · | 3.1% | |
| ROIC | 8.6% | 4.7% | · | 8.4% | 9.2% | 3.8% | · | 3.1% | -18.2% | 1.2% | · | 3.2% | 3.0% | 0.23% | · | 2.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.6 | 3.7 | · | 3.2 | 2.8 | 2.0 | · | 1.9 | 1.9 | 3.5 | · | 3.9 | 3.8 | 3.9 | · | 3.8 | |
| Quick Ratio | 3.0 | 2.3 | · | 1.8 | 1.5 | 1.1 | · | 0.9 | 0.7 | 2.4 | · | 2.9 | 2.8 | 2.8 | · | 2.7 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 213.7 | · | 344.6 | 295.8 | 52.8 | · | 215.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 1.1 | 1.2 | · | 1.3 | 0.9 | 1.1 | · | 1.3 | 1.1 | 1.2 | · | 1.2 | 1.5 | 1.5 | · | 1.6 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.57 | $28.12 | · | $23.71 | $21.49 | $18.93 | · | $16.45 | $15.64 | $24.02 | · | $22.01 | $21.23 | $20.01 | · | $19.00 | |
| Revenue / Share | $8.04 | $6.15 | · | $6.78 | $6.12 | $5.31 | · | $5.81 | $4.78 | $3.88 | · | $4.06 | $4.23 | $3.58 | · | $3.67 | |
| Cash Flow / Share | · | $1.79 | · | · | · | $1.34 | · | · | · | $0.96 | · | · | · | $-0.47 | · | · | |
| Cash / Share | $19.82 | $17.31 | · | $12.52 | $10.07 | $10.02 | · | $6.76 | $5.15 | $14.90 | · | $14.40 | $14.02 | $12.65 | · | $12.10 | |
| EPS (TTM) | $7.85 | $7.08 | · | $5.85 | $4.28 | $0.20 | · | $0.14 | $0.36 | $3.30 | · | $1.89 | $1.63 | $1.45 | · | $3.93 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.82B | $5.36B | · | $4.81B | $4.58B | $4.41B | · | $4.08B | $3.86B | $3.77B | · | $3.61B | $3.51B | $3.47B | · | $3.33B | |
| Net Income TTM | $1.61B | $1.43B | · | $1.19B | $871M | $21M | · | $32M | $97M | $745M | · | $425M | $366M | $324M | · | $876M | |
| Market Cap | $22.78B | $18.82B | · | $16.63B | $13.22B | $11.73B | · | $12.74B | $11.61B | $12.79B | · | $12.95B | $13.90B | $16.12B | · | $14.82B | |
| P/E | 14.4 | 13.3 | · | 14.5 | 15.9 | 302.8 | · | 472.1 | 168.4 | 17.3 | · | 30.6 | 38.2 | 49.8 | · | 17.0 | |
| P/S | 3.9 | 3.5 | · | 3.5 | 2.9 | 2.7 | · | 3.1 | 3.0 | 3.4 | · | 3.6 | 4.0 | 4.6 | · | 4.5 | |
| P/B | 3.6 | 3.3 | · | 3.6 | 3.2 | 3.2 | · | 4.0 | 3.9 | 2.4 | · | 2.6 | 2.9 | 3.6 | · | 3.5 | |
| P / Tangible Book | 3.7 | 3.4 | · | 3.7 | 3.3 | 3.3 | · | 4.2 | 4.1 | 2.4 | · | 2.7 | 3.0 | 3.7 | · | 3.6 | |
| P / Cash Flow | · | 51.0 | · | · | · | 44.1 | · | · | · | 58.5 | · | · | · | -152.7 | · | · | |
| Earnings Yield | 6.9% | 7.5% | · | 6.9% | 6.3% | 0.33% | · | 0.21% | 0.59% | 5.8% | · | 3.3% | 2.6% | 2.0% | · | 5.9% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Operating Margin % | 29.5% | 1.5% | · | 17.1% | 19.6% |
| Net Income | $1.29B | $33M | $598M | $341M | $949M |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 3.3 | 2.0 | · | 3.5 | 3.7 |
| Quick Ratio | 2.0 | 1.0 | · | 2.6 | 2.4 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | · | $892M | $568M |
Institutional owners (13F) 919 filers · $24.0B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
919
Value held
$24.0B
New positions
123
Exited positions
68
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 123 (-4 vs prior Q) | 68 (-29 vs prior Q) | 356 (+47 vs prior Q) | 274 (-17 vs prior Q) | +1.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $3,487,217,729 | 30,762,330 | 14.52% | Shares |
| BlackRock, Inc. | $2,044,188,907 | 18,032,718 | 8.51% | Shares |
| VANGUARD GROUP INC | $1,966,652,336 | 19,911,434 | 8.19% | Shares |
| Dodge & Cox | $1,355,482,475 | 11,957,326 | 5.64% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,249,713,401 | 11,024,289 | 5.20% | Shares |
| STATE STREET CORP | $1,102,124,009 | 9,722,336 | 4.59% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $883,198,076 | 7,791,091 | 3.68% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $603,177,347 | 5,320,901 | 2.51% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $536,515,860 | 4,750,735 | 2.23% | Shares |
| Invesco Ltd. | $462,561,060 | 4,080,461 | 1.93% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $405,321,059 | 3,575,521 | 1.69% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $398,135,284 | 3,512,132 | 1.66% | Shares |
| MORGAN STANLEY | $334,226,735 | 2,948,364 | 1.39% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $311,168,439 | 2,744,958 | 1.30% | Shares |
| Robeco Institutional Asset Management B.V. | $276,795,075 | 2,441,735 | 1.15% | Shares |
| GOLDMAN SACHS GROUP INC | $261,383,430 | 2,305,782 | 1.09% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $258,591,850 | 2,280,803 | 1.08% | Shares |
| TWO SIGMA INVESTMENTS, LP | $227,123,448 | 2,003,559 | 0.95% | Shares |
| NORTHERN TRUST CORP | $199,736,467 | 1,761,966 | 0.83% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $191,854,885 | 1,692,439 | 0.80% | Shares |
| Legal & General Group Plc | $182,053,894 | 1,605,980 | 0.76% | Shares |
| FIRST TRUST ADVISORS LP | $180,015,041 | 1,587,996 | 0.75% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $167,811,569 | 1,480,342 | 0.70% | Shares |
| FMR LLC | $156,637,793 | 1,381,773 | 0.65% | Shares |
| Caisse de depot et placement du Quebec | $155,360,220 | 1,370,503 | 0.65% | Shares |
| MARSHALL WACE, LLP | $148,519,056 | 1,310,154 | 0.62% | Shares |
| HSBC HOLDINGS PLC | $148,336,065 | 1,307,743 | 0.62% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $145,030,732 | 1,540,913 | 0.60% | Shares |
| DEUTSCHE BANK AG\ | $143,172,320 | 1,262,988 | 0.60% | Shares |
| AustralianSuper Pty Ltd | $135,634,220 | 1,196,491 | 0.56% | Shares |
| Amundi | $133,934,668 | 1,181,498 | 0.56% | Shares |
| ROYAL BANK OF CANADA | $128,327,000 | 1,132,050 | 0.53% | Shares |
| NORGES BANK | $126,861,970 | 1,119,107 | 0.53% | Shares |
| Bank of New York Mellon Corp | $110,279,448 | 972,825 | 0.46% | Shares |
| Man Group plc | $108,025,392 | 952,941 | 0.45% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $106,959,694 | 943,540 | 0.45% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $106,304,813 | 937,763 | 0.44% | Shares |
| ARMISTICE CAPITAL, LLC | $102,024,567 | 900,005 | 0.42% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $99,970,937 | 881,889 | 0.42% | Shares |
| JPMORGAN CHASE & CO | $87,335,467 | 761,690 | 0.36% | Shares |
| UBS Group AG | $87,051,865 | 767,924 | 0.36% | Shares |
| Sound Shore Management Inc /CT/ | $85,895,479 | 757,723 | 0.36% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $82,953,901 | 731,774 | 0.35% | Shares |
| Gotham Asset Management, LLC | $81,567,621 | 719,545 | 0.34% | Shares |
| Pictet Asset Management Holding SA | $81,315,880 | 713,354 | 0.34% | Shares |
| BANK OF AMERICA CORP /DE/ | $76,653,013 | 676,191 | 0.32% | Shares |
| MACKENZIE FINANCIAL CORP | $71,967,956 | 634,862 | 0.30% | Shares |
| CITIGROUP INC | $66,477,819 | 586,431 | 0.28% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $65,633,852 | 578,986 | 0.27% | Shares |
| FRANKLIN RESOURCES INC | $63,330,037 | 558,663 | 0.26% | Shares |
Activists & 5%+ owners 7 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB3 LLC, FBB Associates ×21 filings | May 11, 2026 | 15.60% | Amendment | Passive investment | SEC |
| Incyte Corporation ×3 filings | Aug. 14, 2023 | · | Initial filing | Capital structure | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB Associates ×2 filings | June 15, 2012 | · | Initial filing | · | SEC |
| Julian C. Baker, Felix J. Baker ×12 filings | Oct. 1, 2009 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Feb. 25, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Sept. 29, 2003 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Aug. 15, 2002 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 61 insiders · 34 officers · 17 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| William Meury | Chief Executive Officer | July 16, 2026 A | 183,129 | 0 | 0 | $0 |
| Suketu Upadhyay | EVP & Chief Financial Officer | May 4, 2026 A | 26,343 | 0 | 0 | $0 |
| Christiana Stamoulis | EVP & Chief Financial Officer | July 15, 2025 A | 125,759 | 0 | 0 | $0 |
| David W Gryska | Executive Vice President, CFO | July 16, 2018 F | 10,235 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | June 5, 2014 M | 8,500 | 0 | 0 | $0 |
| Pablo J Cagnoni | President, Global Head of R&D | Sept. 15, 2026 M | 183,200 | 0 | 9 | $-14,102,143 |
| David H Gardner | EVP, Chief Strategy Officer | Sept. 22, 2026 F | 15,904 | 0 | 0 | $0 |
| Ramitpal K Basi | EVP, Human Resources | Aug. 25, 2026 F | 10,993 | 0 | 0 | $0 |
| Patrick A Mayes | EVP & Chief Scientific Officer | Aug. 5, 2026 M | 61,441 | 0 | 15 | $-6,562,989 |
| Lee Heeson | EVP, Head of Incyte Intl | July 23, 2026 A | 38,041 | 0 | 1 | $-289,017 |
| Michael James Morrissey | EVP, Head of Tech. Operations | July 23, 2026 A | 34,065 | 0 | 3 | $-5,675,002 |
| Richard A. Hoffman | EVP & General Counsel | July 16, 2026 A | 16,861 | 0 | 0 | $0 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | July 16, 2026 A | 71,797 | 0 | 2 | $-1,309,770 |
| Thomas Tray | Principal Accounting Officer | July 16, 2026 A | 21,699 | 0 | 6 | $-878,953 |
| Steven H Stein | CMO & Head of Late-Stage Dev. | July 16, 2026 A | 30,916 | 0 | 6 | $-7,856,771 |
| Matteo Trotta | EVP, GM, Dermatology US | March 25, 2026 F | 14,882 | 0 | 0 | $0 |
| Sheila A. Denton | EVP & General Counsel | Nov. 17, 2025 M | 26,569 | 0 | 5 | $-465,184 |
| Vijay K Iyengar | EVP, GMAPPS | July 16, 2025 S | 40,540 | 0 | 0 | $0 |
| Barry P Flannelly | EVP & General Manager US | July 16, 2025 S | 35,149 | 0 | 0 | $0 |
| Paula J Swain | EVP, Human Resources | July 15, 2025 A | 106,482 | 0 | 0 | $0 |
| Jonathan Elliott Dickinson | EVP, General Manager, Europe | Sept. 12, 2024 S | 36,390 | 0 | 0 | $0 |
| Dashyant Dhanak | EVP & Chief Scientific Officer | July 14, 2023 A | 58,968 | 0 | 0 | $0 |
| Maria E Pasquale | EVP & General Counsel | July 14, 2023 A | 69,724 | 0 | 0 | $0 |
| Paul Trower | Principal Accounting Officer | Jan. 19, 2022 A | 32,268 | 0 | 0 | $0 |
| Yao Wenqing | EVP, Head of Discovery Chem | July 2, 2021 A | 98,575 | 0 | 0 | $0 |
| Reid M Huber | EVP, Chief Scientific Officer | July 16, 2018 F | 34,571 | 0 | 0 | $0 |
| Eric H. Siegel | EVP, General Counsel | Sept. 13, 2017 F | 21,053 | 0 | 0 | $0 |
| Richard S Levy | EVP, Chief Drug Dev Officer | Jan. 6, 2016 M | 16,926 | 0 | 0 | $0 |
| James M Daly | EVP, Chief Commercial Officer | June 23, 2015 M | 3,521 | 0 | 0 | $0 |
| Patricia S Andrews | Chief Commercial Officer | Jan. 19, 2012 A | · | 0 | 0 | $0 |
| Patricia A Schreck | EVP, General Counsel | May 10, 2011 M | 4,500 | 0 | 0 | $0 |
| Brian W Metcalf | Chief Drug Discovery Scientist | April 11, 2011 M | 66,504 | 0 | 0 | $0 |
| Steven M. Friedman | EVP, Biology & Preclinical Dev | May 18, 2010 A | 38,137 | 0 | 0 | $0 |
| John A Keller | Chief Business Officer | Feb. 8, 2008 A | · | 0 | 0 | $0 |
| Paul J Clancy | Director | Sept. 30, 2026 A | 25,838 | 0 | 1 | $-1,423,950 |
| Edmund Harrigan | Director | Sept. 30, 2026 A | 23,225 | 0 | 0 | $0 |
| Katherine A High | Director | June 8, 2026 A | 14,983 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Director | June 8, 2026 A | 20,968 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Director | June 8, 2026 A | 24,424 | 0 | 0 | $0 |
| Otis W Brawley | Director | June 8, 2026 A | 12,894 | 0 | 0 | $0 |
| Herve Hoppenot | Director | Dec. 8, 2025 F | 326,803 | 0 | 1 | $-19,773,750 |
| Susanne Schaffert | Director | June 10, 2025 A | 7,389 | 0 | 0 | $0 |
| Wendy L Dixon | Director | March 31, 2022 A | 17,768 | 0 | 0 | $0 |
| Paul A Friedman, M.D. | Director | May 26, 2020 A | 256,813 | 0 | 0 | $0 |
| Paul A Brooke | Director | March 31, 2020 A | 221,911 | 0 | 0 | $0 |
| Barry A Ariko | Director | March 12, 2015 M | 45,834 | 0 | 0 | $0 |
| Richard U De Schutter | Director | March 5, 2015 M | 92,290 | 0 | 0 | $0 |
| Roy A Whitfield | Director | Dec. 17, 2013 M | 666,082 | 0 | 0 | $0 |
| John F Niblack | Director | May 20, 2011 A | · | 0 | 0 | $0 |
| Fred B Craves | Director | June 1, 2005 A | 196,793 | 0 | 0 | $0 |
| DAMIAL FOUNDATION INC | 10% owner | Feb. 11, 2004 S | · | 0 | 0 | $0 |
| Bonnie J Tisch | 10% owner | Jan. 14, 2004 S | · | 0 | 0 | $0 |
| Laurent Chardonnet | · | March 30, 2015 M | 2,905 | 0 | 0 | $0 |
| Julian C. Baker | · | May 30, 2013 A | 66,340 | 0 | 0 | $0 |
| Matthew Emmens | · | May 22, 2008 A | · | 0 | 0 | $0 |
| HURLEY SCOTT W | · | Jan. 19, 2005 A | · | 0 | 0 | $0 |
| Daniel R Tisch | · | Aug. 12, 2004 P | 1,216,661 | 0 | 0 | $0 |
| TISCH THOMAS J | · | Aug. 12, 2004 P | 1,416,661 | 0 | 0 | $0 |
| James S Tisch | · | Aug. 12, 2004 P | 1,216,661 | 0 | 0 | $0 |
| Andrew H Tisch | · | Aug. 12, 2004 P | 1,216,661 | 0 | 0 | $0 |
| Jon S Saxe | · | March 30, 2004 M | 80,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 149 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IDNA · iShares Trust | 3.73% | 77,294 SH | Sept. 11, 2026 | Daily |
| SAWG · ETF Series Solutions | 3.28% | 792 NS | July 31, 2026 | N-PORT |
| BUL · Pacer Funds Trust | 3.05% | 33,574 NS | July 31, 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2.55% | 90,459 SH | Oct. 2, 2026 | Daily |
| SMRI · EA Series Trust | 2.07% | 111,793 NS | July 31, 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 1.99% | 344 NS | July 31, 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1.94% | 27,325 SH | Oct. 2, 2026 | Daily |
| UPGD · Invesco Exchange-Traded Fund Trust | 1.90% | 18,656 SH | Oct. 2, 2026 | Daily |
| SPGP · Invesco Exchange-Traded Fund Trust | 1.86% | 323,409 SH | Oct. 2, 2026 | Daily |
| IBB · iShares Trust | 1.81% | 1,512,762 SH | Sept. 11, 2026 | Daily |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.80% | 10,419 NS | July 31, 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.78% | 156,306 NS | July 31, 2026 | N-PORT |
| RPG · Invesco Exchange-Traded Fund Trust | 1.63% | 270,969 SH | Oct. 2, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.59% | 14,343 SH | Oct. 2, 2026 | Daily |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.54% | 114,153 SH | Oct. 2, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.52% | 12,506 NS | July 31, 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1.52% | 465,439 NS | July 31, 2026 | N-PORT |
| GURU · Global X Funds | 1.37% | 7,010 NS | July 31, 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1.19% | 119,789 SH | Oct. 2, 2026 | Daily |
| LSVD · ADVISORS' INNER CIRCLE FUND | 1.04% | 56,481 NS | July 31, 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 1.03% | 113,368 NS | July 31, 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.82% | 9,194 SH | Oct. 2, 2026 | Daily |
| INFO · Harbor ETF Trust | 0.81% | 57,450 NS | July 31, 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.77% | 992 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.77% | 32,018 NS | July 31, 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.73% | 14,779 NS | July 31, 2026 | N-PORT |
| COWG · Pacer Funds Trust | 0.72% | 132,772 NS | July 31, 2026 | N-PORT |
| BRNY · EA Series Trust | 0.57% | 27,866 NS | July 31, 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0.56% | 70,403 SH | Oct. 2, 2026 | Daily |
| ESMV · iShares Trust | 0.54% | 339 SH | Sept. 11, 2026 | Daily |
| VBK · VANGUARD INDEX FUNDS | 0.53% | 2,249,253 SH | Aug. 19, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.51% | 24,639 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0.50% | 774,539 NS | July 31, 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.49% | 29,166 NS | July 31, 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.49% | 2,011 NS | July 31, 2026 | N-PORT |
| TECB · iShares Trust | 0.49% | 19,516 SH | Sept. 11, 2026 | Daily |
| VLLU · Harbor ETF Trust | 0.49% | 189 NS | July 31, 2026 | N-PORT |
| USMV · iShares Trust | 0.47% | 910,173 SH | Sept. 11, 2026 | Daily |
| VFQY · VANGUARD WELLINGTON FUND | 0.46% | 19,147 SH | Aug. 19, 2026 | Daily |
| ESLV · Strategy Shares | 0.45% | 537 NS | July 31, 2026 | N-PORT |
| SDG · iShares Trust | 0.42% | 5,697 SH | Sept. 11, 2026 | Daily |
| ACWV · iShares, Inc. | 0.41% | 111,137 SH | Sept. 11, 2026 | Daily |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.39% | 15,107 NS | July 31, 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.38% | 49,720 NS | July 31, 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.35% | 72,339 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.33% | 97,043 SH | Sept. 11, 2026 | Daily |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.32% | 12,427 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.29% | 80,584 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.28% | 508,499 SH | Aug. 19, 2026 | Daily |
| VFMF · VANGUARD WELLINGTON FUND | 0.27% | 16,793 SH | Aug. 19, 2026 | Daily |
| IXJ · iShares Trust | 0.26% | 88,044 SH | Sept. 11, 2026 | Daily |
| SIZE · iShares Trust | 0.25% | 8,715 SH | Sept. 11, 2026 | Daily |
| FBUF · Fidelity Greenwood Street Trust | 0.25% | 498 NS | July 31, 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0.24% | 997 NS | July 31, 2026 | N-PORT |
| LGDX · Tidal Trust III | 0.23% | 2,756 NS | July 31, 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.23% | 3,894,602 SH | Aug. 19, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.23% | 3,302 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.22% | 437 NS | July 31, 2026 | N-PORT |
| IWS · iShares Trust | 0.20% | 247,446 SH | Sept. 11, 2026 | Daily |
| EUSA · iShares, Inc. | 0.20% | 30,370 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.19% | 1,548,872 SH | Oct. 2, 2026 | Daily |
| FTLS · First Trust Exchange-Traded Fund III | 0.19% | 38,962 NS | July 31, 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0.18% | 13,826 NS | July 31, 2026 | N-PORT |
| IMCV · iShares Trust | 0.17% | 16,093 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.17% | 30,550 SH | Aug. 19, 2026 | Daily |
| ESUM · Strategy Shares | 0.16% | 2,509 NS | July 31, 2026 | N-PORT |
| SPHQ · Invesco Exchange-Traded Fund Trust | 0.16% | 260,988 SH | Oct. 2, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.16% | 91,827 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.16% | 12,315 SH | Aug. 19, 2026 | Daily |
| ESLG · Strategy Shares | 0.16% | 307 NS | July 31, 2026 | N-PORT |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 0.16% | 106,670 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.15% | 678,309 SH | Sept. 11, 2026 | Daily |
| IMCB · iShares Trust | 0.14% | 19,540 SH | Sept. 11, 2026 | Daily |
| EVUS · iShares Trust | 0.12% | 3,715 SH | Sept. 11, 2026 | Daily |
| XOEF · iShares Trust | 0.12% | 213 SH | Sept. 11, 2026 | Daily |
| IMCG · iShares Trust | 0.12% | 37,577 SH | Sept. 11, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.11% | 146,271 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.10% | 19,945 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.10% | 41,885 SH | Oct. 2, 2026 | Daily |
| ESGU · iShares Trust | 0.10% | 141,033 SH | Sept. 11, 2026 | Daily |
| CATH · Global X Funds | 0.10% | 10,371 NS | July 31, 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0.09% | 180,160 SH | Oct. 2, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.09% | 4,162 NS | July 31, 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 6,132 SH | Oct. 2, 2026 | Daily |
| USXF · iShares Trust | 0.08% | 10,050 SH | Sept. 11, 2026 | Daily |
| PALC · Pacer Funds Trust | 0.08% | 1,398 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.08% | 21,901 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.07% | 298,392 NS | July 31, 2026 | N-PORT |
| GARP · iShares Trust | 0.07% | 17,562 SH | Sept. 11, 2026 | Daily |
| SUSL · iShares Trust | 0.06% | 6,008 SH | Sept. 11, 2026 | Daily |
| CHRI · Global X Funds | 0.06% | 41 NS | July 31, 2026 | N-PORT |
| DSI · iShares Trust | 0.06% | 25,952 SH | Sept. 11, 2026 | Daily |
| IVW · iShares Trust | 0.06% | 354,438 SH | Sept. 11, 2026 | Daily |
| IUSG · iShares Trust | 0.06% | 147,395 SH | Sept. 11, 2026 | Daily |
| IWD · iShares Trust | 0.05% | 367,740 SH | Sept. 11, 2026 | Daily |
| GLOF · iShares Trust | 0.05% | 840 SH | Sept. 11, 2026 | Daily |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.05% | 124,582 SH | Aug. 19, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.05% | 100,000 SH | Aug. 19, 2026 | Daily |
| REVS · Columbia ETF Trust I | 0.05% | 1,396 NS | July 31, 2026 | N-PORT |
| EGLE · Global X Funds | 0.05% | 9 NS | July 31, 2026 | N-PORT |
| HAPI · Harbor ETF Trust | 0.05% | 1,975 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.05% | 38,893 SH | Oct. 2, 2026 | Daily |
| DFVX · Dimensional ETF Trust | 0.05% | 1,993 NS | July 31, 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.04% | 3,572 SH | Oct. 2, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.04% | 43,168 NS | July 31, 2026 | N-PORT |
| TOV · EA Series Trust | 0.04% | 910 NS | July 31, 2026 | N-PORT |
| TOPC · iShares Trust | 0.04% | 100 SH | Sept. 11, 2026 | Daily |
| ILCV · iShares Trust | 0.04% | 3,819 SH | Sept. 11, 2026 | Daily |
| XVV · iShares Trust | 0.04% | 1,907 SH | Sept. 11, 2026 | Daily |
| XYLG · Global X Funds | 0.03% | 186 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.03% | 10 NS | July 31, 2026 | N-PORT |
| XRMI · Global X Funds | 0.03% | 133 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.03% | 2,115,770 SH | Sept. 11, 2026 | Daily |
| XYLD · Global X Funds | 0.03% | 8,564 NS | July 31, 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.03% | 4,458 SH | Oct. 2, 2026 | Daily |
| PTLC · Pacer Funds Trust | 0.03% | 8,472 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.03% | 3,242 SH | Sept. 11, 2026 | Daily |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.03% | 22,989 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.03% | 2,822 NS | July 31, 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.03% | 1,013 SH | Oct. 2, 2026 | Daily |
| BKLC · BNY Mellon ETF Trust | 0.03% | 13,892 NS | July 31, 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.03% | 29,419 SH | Oct. 2, 2026 | Daily |
| VOO · VANGUARD INDEX FUNDS | 0.03% | 4,357,457 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.03% | 5,391,866 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.03% | 27,427 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.03% | 13,959 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.03% | 37,474 SH | Aug. 19, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.03% | 51,979 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.03% | 12 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.03% | 114,458 SH | Sept. 11, 2026 | Daily |
| IYY · iShares Trust | 0.03% | 7,092 SH | Sept. 11, 2026 | Daily |
| SPUU · Direxion Shares ETF Trust | 0.03% | 634 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.03% | 4,037 NS | July 31, 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0.03% | 95,298 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.03% | 45,601 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.03% | 215,857 SH | Sept. 11, 2026 | Daily |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.03% | 23,005 SH | Oct. 2, 2026 | Daily |
| ACVF · ETF Opportunities Trust | 0.03% | 345 NS | July 31, 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.03% | 13,186 NS | July 31, 2026 | N-PORT |
| ILCG · iShares Trust | 0.03% | 6,647 SH | Sept. 11, 2026 | Daily |
| PHDG · Invesco Actively Managed Exchange-T… | 0.03% | 133 SH | Oct. 2, 2026 | Daily |
| TOK · iShares Trust | 0.03% | 485 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.03% | 4,582 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.02% | 1,167 NS | July 31, 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.02% | 13,118 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.02% | 14,482 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.02% | 55,495 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.02% | 142,324 SH | Aug. 19, 2026 | Daily |
| CRBN · iShares Trust | 0.01% | 876 SH | Sept. 11, 2026 | Daily |
INCY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 35 analysts
BUY
Median target
$130.00
+13.1%
8 22.9%
Strong Buy
10 28.6%
Buy
17 48.6%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
23 analysts · 2026-09-29Mean target $127.96 +11.3%
Now
Current price $114.97
Low$86.00
Mean$127.96
High$155.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| RVMD | · | · | · | · | · | · |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | · |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
BLUECHIP_DIP
Stopped out
risk 1
reward 5.00
entry
$95.85
R:R 5.00
BLUECHIP_DIP
Expired
risk 1
reward 5.00
entry
$95.27
R:R 5.00
BLUECHIP_DIP
Expired
risk 1
reward 1.30
entry
$91.77
R:R 1.30
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Jul 28, 2026